FDA approved Rexulti to be the first antipsychotic for treating agitation in elderly patients with dementia

In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.

Related Keywords

Oregon ,United States ,Rajesh Narendran ,Nina Zeldes ,Lon Schneider ,Robert Whitaker ,Oderick Turner ,Danielle Ellis ,Alliance For Aging Research ,Drug Administration ,Us Centers For Medicare ,Medicaid Services ,Leaders Engage On Alzheimer Research ,Advisory Committee ,Oregon Health Science University ,Lundbeck ,Keck School ,Southern California ,Drug Evaluation ,Aging Research ,Leaders Engage ,Oregon Health ,Science University ,Antipsychotic ,Dementia ,Aging ,Wood ,Forecasting ,Medicaid ,Medicare ,Nursing ,Placebo ,Research ,